论文部分内容阅读
目的:分析2型糖尿病患者行瑞格列奈、二甲双胍联合疗法的临床效果。方法:调查对象从我院2012年4月-2014年7月收治2型糖尿病患者中抽选,将120例分组后行不同疗法,即:对照组(二甲双胍)、实验组(瑞格列奈、二甲双胍),预后评估总体效果。结果:实验组预后缓解率为96.7%,高于83.3%的对照组,有区别,P<0.05;实验组预后血糖、血红蛋白指标改善程度高于对照组,有区别,P<0.05。结论:临床借助瑞格列奈、二甲双胍联合疗法治疗2型糖尿病患者作用突出,可改善血糖指标,提高疾病效果,值得学习。
Objective: To analyze the clinical effect of combination therapy of repaglinide and metformin in patients with type 2 diabetes mellitus. Methods: The subjects from our hospital from April 2012 to July 2014 were treated patients with type 2 diabetes, 120 patients were divided into groups after the different treatments, namely: the control group (metformin), the experimental group (repaglinide, Metformin), prognosis to assess the overall effect. Results: The remission rate of experimental group was 96.7%, higher than 83.3%, there was difference (P <0.05). The prognosis of experimental group was higher than that of control group (P <0.05). Conclusion: The combination of repaglinide and metformin in clinical treatment of type 2 diabetes patients with outstanding effect, can improve blood glucose, improve disease effect, it is worth learning.